Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05342675 · ClinicalTrials.gov registry record · NA

Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy

A NA study of Lung Cancer and Pneumothorax, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
54
Enrollment target
2
Study locations

NCT05342675 is a NA study of Lung Cancer and Pneumothorax that has completed, run by University of California, San Francisco. The registered enrollment target is 54 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05342675, a NA study of Lung Cancer and Pneumothorax, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
54 participants
Enrollment target
2
Study locations

Study Summary

Pneumothorax is the most common complication after CT-guided lung biopsy, and several techniques have been proposed to reduce the risk. Among them, rapid rollover is the maneuver to immediately reposition the patient, with biopsy-side down after removal of biopsy needle. It has been theorized that the technique reduces the size of alveoli surrounding the needle tract, leading to airway closure and reduction in the alveolar-to-pleural pressure gradient, thereby preventing pneumothorax. The aim of this study is to evaluate the effectiveness of rapid rollover in reducing the risk of radiographically detectable pneumothorax and the rate of chest tube insertion. Patients undergoing CT-guided lung biopsy for any indication will be recruited and randomized into either rapid rollover group or control group. In the control group, CT guided lung biopsy will be performed per standard protocols; in the rapid rollover group, the biopsy will also be performed per the same protocol with the addition of rapid rollover at the end of the procedure. For both groups, the primary outcome would be new or enlarging pneumothorax detected on post-biopsy radiographs, and the secondary outcome would be the risk of pneumothorax necessitating chest tube insertion, all complications associated with CT guided lung biopsy, time to complication development, and patient experience in each arm.

Conditions Studied

Interventions

  • PROCEDURE Rapid Rollover

Study Locations (2)

California

  • Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2022-09-15
Est. Completion 2024-06-30
Phase NA

What the Registry Record Tells You About NCT05342675

The ClinicalTrials.gov registry entry for NCT05342675 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Rapid Rollover is the first listed.

NCT05342675 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05342675 about?

NCT05342675 is a clinical study titled "Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy". Pneumothorax is the most common complication after CT-guided lung biopsy, and several techniques have been proposed to reduce the risk. Among them, rapid rollover is the maneuver to immediately reposition the patient, with biopsy-side down after removal of biopsy needle. It has been theorized that t...

What is the current status of trial NCT05342675?

This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2022-09-15. Estimated completion is 2024-06-30.

What conditions does trial NCT05342675 study?

This clinical trial studies the following conditions: Lung Cancer, Pneumothorax.

What interventions are being tested in trial NCT05342675?

The interventions under investigation include: Rapid Rollover (PROCEDURE).

Who is sponsoring clinical trial NCT05342675?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05342675 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.